Exploring the Potential Mechanism of Qi-Shen-Di-Huang Drug Formulary for Myasthenia Gravis (MG) based on UHPLC-QE-MS Network Pharmacology and Molecular Docking Techniques

<table class="table-group" id="tab2"><tr><td><table class="table"><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr class="thead"><td class="align_left">Core Targets</td><td class="align_center">PDB ID</td><td class="align_center">Compound Name</td><td class="align_center">Binding energy</td></tr><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr><td class="align_left">AKT1</td><td class="align_center">P31749</td><td class="align_center">Quercetin</td><td class="align_center">−6</td></tr><tr><td class="align_left"> </td><td class="align_center"> </td><td class="align_center">Luteolin</td><td class="align_center">−6.3</td></tr><tr><td class="align_left"> </td><td class="align_center"> </td><td class="align_center">Wogonin</td><td class="align_center">−6</td></tr><tr><td class="align_left"> </td><td class="align_center"> </td><td class="align_center">Kaempferol</td><td class="align_center">−5.9</td></tr><tr><td class="align_left"> </td><td class="align_center"> </td><td class="align_center">Fisetin</td><td class="align_center">−6</td></tr><tr><td class="align_left"> </td><td class="align_center"> </td><td class="align_center">Epigallocatechin-3-gallate</td><td class="align_center">−7.6</td></tr><tr class="table-tr"><td colspan="4"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

Evidence-Based Complementary and Alternative Medicine

tab2

Table 2

Table 2: Exploring the Potential Mechanism of Qi-Shen-Di-Huang Drug Formulary for Myasthenia Gravis (MG) based on UHPLC-QE-MS Network Pharmacology and Molecular Docking Techniques 

Table 2 | Exploring the Potential Mechanism of Qi-Shen-Di-Huang Drug Formulary for Myasthenia Gravis (MG) based on UHPLC-QE-MS Network Pharmacology and Molecular Docking Techniques 